经皮耳迷走神经刺激治疗失眠症:系统回顾和荟萃分析。

IF 3.2 3区 医学 Q2 CLINICAL NEUROLOGY
Helen Michaela de Oliveira, Mariano Gallo Ruelas, Camilo André Viana Diaz, Guilherme Oliveira de Paula, Pablo Ramon Fruett da Costa, Julie G Pilitsis
{"title":"经皮耳迷走神经刺激治疗失眠症:系统回顾和荟萃分析。","authors":"Helen Michaela de Oliveira, Mariano Gallo Ruelas, Camilo André Viana Diaz, Guilherme Oliveira de Paula, Pablo Ramon Fruett da Costa, Julie G Pilitsis","doi":"10.1016/j.neurom.2025.04.001","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Insomnia is a prevalent condition with significant impacts on quality of life, often accompanied by anxiety and depression. Transcutaneous auricular vagus nerve stimulation (taVNS) has emerged as a noninvasive therapeutic option, but its efficacy and mechanisms remain to be fully elucidated. This systematic review and meta-analysis aimed to evaluate the clinical effectiveness of taVNS on insomnia, as measured by the Pittsburgh Sleep Quality Index (PSQI) and the Insomnia Severity Index (ISI).</p><p><strong>Materials and methods: </strong>We systematically searched PubMed, Embase, and the CENTRAL data bases up to January 2025 for clinical trials comparing taVNS in patients with insomnia. This study followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Statistical analyses were performed using R version 4.3.2. The risk of bias was assessed using the Risk Of Bias In Non-randomized Studies - of Interventions and Risk Of Bias in Randomized Studies tools, and the quality of evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) assessment. The study was registered in the International Prospective Register of Systematic Reviews under protocol CRD42025634016.</p><p><strong>Results: </strong>Of 313 studies screened, six met the inclusion criteria and were included, encompassing a total of 336 patients. The pooled analysis showed statistically significant improvements in sleep quality and insomnia severity, as measured by PSQI (MD = -3.60; 95% CI = -4.98 to -2.22; p < 0.01; GRADE = Low evidence) and ISI (MD = -5.24; 95% CI = -9.02 to -1.46; p < 0.01; GRADE = Very low evidence) scores. Moreover, the studies reported improvements in sleep subscales, including overall sleep quality, latency, duration, and efficiency. Adverse effects were minimal and manageable, highlighting the safety profile of taVNS and supporting its potential as a well-tolerated, noninvasive treatment option for insomnia.</p><p><strong>Conclusion: </strong>taVNS can significantly relieve insomnia, supported by its neural and autonomic pathways modulation. These findings highlight taVNS as a promising, safe, and noninvasive treatment for insomnia, warranting further research to optimize its application and expand its use in broader populations.</p>","PeriodicalId":19152,"journal":{"name":"Neuromodulation","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Transcutaneous Auricular Vagus Nerve Stimulation in Insomnia: A Systematic Review and Meta-Analysis.\",\"authors\":\"Helen Michaela de Oliveira, Mariano Gallo Ruelas, Camilo André Viana Diaz, Guilherme Oliveira de Paula, Pablo Ramon Fruett da Costa, Julie G Pilitsis\",\"doi\":\"10.1016/j.neurom.2025.04.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Insomnia is a prevalent condition with significant impacts on quality of life, often accompanied by anxiety and depression. Transcutaneous auricular vagus nerve stimulation (taVNS) has emerged as a noninvasive therapeutic option, but its efficacy and mechanisms remain to be fully elucidated. This systematic review and meta-analysis aimed to evaluate the clinical effectiveness of taVNS on insomnia, as measured by the Pittsburgh Sleep Quality Index (PSQI) and the Insomnia Severity Index (ISI).</p><p><strong>Materials and methods: </strong>We systematically searched PubMed, Embase, and the CENTRAL data bases up to January 2025 for clinical trials comparing taVNS in patients with insomnia. This study followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Statistical analyses were performed using R version 4.3.2. The risk of bias was assessed using the Risk Of Bias In Non-randomized Studies - of Interventions and Risk Of Bias in Randomized Studies tools, and the quality of evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) assessment. The study was registered in the International Prospective Register of Systematic Reviews under protocol CRD42025634016.</p><p><strong>Results: </strong>Of 313 studies screened, six met the inclusion criteria and were included, encompassing a total of 336 patients. The pooled analysis showed statistically significant improvements in sleep quality and insomnia severity, as measured by PSQI (MD = -3.60; 95% CI = -4.98 to -2.22; p < 0.01; GRADE = Low evidence) and ISI (MD = -5.24; 95% CI = -9.02 to -1.46; p < 0.01; GRADE = Very low evidence) scores. Moreover, the studies reported improvements in sleep subscales, including overall sleep quality, latency, duration, and efficiency. Adverse effects were minimal and manageable, highlighting the safety profile of taVNS and supporting its potential as a well-tolerated, noninvasive treatment option for insomnia.</p><p><strong>Conclusion: </strong>taVNS can significantly relieve insomnia, supported by its neural and autonomic pathways modulation. These findings highlight taVNS as a promising, safe, and noninvasive treatment for insomnia, warranting further research to optimize its application and expand its use in broader populations.</p>\",\"PeriodicalId\":19152,\"journal\":{\"name\":\"Neuromodulation\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-05-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuromodulation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.neurom.2025.04.001\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuromodulation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.neurom.2025.04.001","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:失眠是一种影响生活质量的普遍疾病,常伴有焦虑和抑郁。经皮耳迷走神经刺激(taVNS)已成为一种无创治疗选择,但其疗效和机制仍有待充分阐明。本系统综述和荟萃分析旨在通过匹兹堡睡眠质量指数(PSQI)和失眠严重程度指数(ISI)来评估taVNS对失眠的临床疗效。材料和方法:我们系统地检索PubMed、Embase和CENTRAL数据库,检索截至2025年1月比较taVNS在失眠患者中的临床试验。本研究遵循系统评价和荟萃分析指南的首选报告项目。采用R 4.3.2版本进行统计分析。使用非随机研究的偏倚风险-干预和随机研究的偏倚风险工具评估偏倚风险,使用推荐评估、发展和评价分级(GRADE)评估评估证据质量。该研究已在国际前瞻性系统评价注册中注册,注册方案为CRD42025634016。结果:在筛选的313项研究中,有6项符合纳入标准,共纳入336例患者。合并分析显示,睡眠质量和失眠严重程度有统计学上的显著改善,以PSQI (MD = -3.60;95% CI = -4.98 ~ -2.22;P < 0.01;GRADE =低证据)和ISI (MD = -5.24;95% CI = -9.02 ~ -1.46;P < 0.01;GRADE(非常低证据)分数。此外,这些研究报告了睡眠亚量表的改善,包括整体睡眠质量、潜伏期、持续时间和效率。不良反应最小且可控,突出了taVNS的安全性,并支持其作为一种耐受性良好、无创治疗失眠的选择的潜力。结论:taVNS对失眠有明显的缓解作用,其作用机制与神经和自主神经通路的调节有关。这些发现强调了taVNS作为一种有前景的、安全的、无创的失眠治疗方法,值得进一步研究以优化其应用并扩大其在更广泛人群中的应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Transcutaneous Auricular Vagus Nerve Stimulation in Insomnia: A Systematic Review and Meta-Analysis.

Objectives: Insomnia is a prevalent condition with significant impacts on quality of life, often accompanied by anxiety and depression. Transcutaneous auricular vagus nerve stimulation (taVNS) has emerged as a noninvasive therapeutic option, but its efficacy and mechanisms remain to be fully elucidated. This systematic review and meta-analysis aimed to evaluate the clinical effectiveness of taVNS on insomnia, as measured by the Pittsburgh Sleep Quality Index (PSQI) and the Insomnia Severity Index (ISI).

Materials and methods: We systematically searched PubMed, Embase, and the CENTRAL data bases up to January 2025 for clinical trials comparing taVNS in patients with insomnia. This study followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Statistical analyses were performed using R version 4.3.2. The risk of bias was assessed using the Risk Of Bias In Non-randomized Studies - of Interventions and Risk Of Bias in Randomized Studies tools, and the quality of evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) assessment. The study was registered in the International Prospective Register of Systematic Reviews under protocol CRD42025634016.

Results: Of 313 studies screened, six met the inclusion criteria and were included, encompassing a total of 336 patients. The pooled analysis showed statistically significant improvements in sleep quality and insomnia severity, as measured by PSQI (MD = -3.60; 95% CI = -4.98 to -2.22; p < 0.01; GRADE = Low evidence) and ISI (MD = -5.24; 95% CI = -9.02 to -1.46; p < 0.01; GRADE = Very low evidence) scores. Moreover, the studies reported improvements in sleep subscales, including overall sleep quality, latency, duration, and efficiency. Adverse effects were minimal and manageable, highlighting the safety profile of taVNS and supporting its potential as a well-tolerated, noninvasive treatment option for insomnia.

Conclusion: taVNS can significantly relieve insomnia, supported by its neural and autonomic pathways modulation. These findings highlight taVNS as a promising, safe, and noninvasive treatment for insomnia, warranting further research to optimize its application and expand its use in broader populations.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Neuromodulation
Neuromodulation 医学-临床神经学
CiteScore
6.40
自引率
3.60%
发文量
978
审稿时长
54 days
期刊介绍: Neuromodulation: Technology at the Neural Interface is the preeminent journal in the area of neuromodulation, providing our readership with the state of the art clinical, translational, and basic science research in the field. For clinicians, engineers, scientists and members of the biotechnology industry alike, Neuromodulation provides timely and rigorously peer-reviewed articles on the technology, science, and clinical application of devices that interface with the nervous system to treat disease and improve function.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信